Paratek Pharmaceuticals

Developing transformative solutions for patients with infectious diseases.

Launch date

1996

Employees

Market cap

Enterprise valuation

€324m (Public information from Sep 2023)

Boston Massachusetts (HQ)

https://www.paratekpharma.com/

https://twitter.com/paratekpharma https://www.facebook.com/paratekpharma https://www.linkedin.com/company/paratek-pharmaceuticals-inc-

View job openings

Revenues, earnings & profits over time

USD	2016	2017	2018	2019	2020	2021	2022
Revenues	-	12.6m	17.1m	16.5m	43.5m	121m	151m
% growth	-	-	36 %	(3 %)	163 %	178 %	25 %
EBITDA	-	(82.0m)	(101m)	(112m)	(73.9m)	(40.7m)	(44.9m)
% EBITDA margin	-	(650 %)	(589 %)	(678 %)	(170 %)	(34 %)	(30 %)
Profit	-	(89.1m)	(112m)	(129m)	(96.5m)	(59.1m)	(63.6m)
% profit margin	-	(706 %)	(656 %)	(778 %)	(222 %)	(49 %)	(42 %)
EV / revenue	-	32.3x	8.3x	10.8x	9.4x	1.5x	1.2x
EV / EBITDA	-	-5.0x	-1.4x	-1.6x	-5.6x	-4.5x	-4.0x
R&D budget	86.9m	60.1m	57.5m	39.6m	23.9m	30.4m	37.8m
R&D % of revenue	-	476 %	336 %	239 %	55 %	25 %	25 %

Source: Dealroom estimates

Date	Investors	Amount	Round
-	InterWest Partners New Enterprise Associates	N/A	-
May 2006	N/A	N/A	IPO
Oct 2007	Aisling Capital Pacific Growth Equities	$40.0m	Post IPO Equity
Jul 2014	Aisling Capital Omega Funds	$93.0m	Post IPO Debt
May 2015*	N/A	$71.1m	Post IPO Equity
Jan 2021	R-Bridge Healthcare Investment Advisory	$60.0m	Post IPO Debt
Jun 2023*	Novo Ventures Gurnet Point Capital	$472m Valuation: $472m 3.1x EV/LTM Revenues -10.5x EV/LTM EBITDA	Acquisition
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

Transcept Pharmaceuticals

ACQUISITION by Paratek Pharmaceuticals Oct 2014